Search clinical trials for: PD-1, Anti-PD-1

Total 131783 results

Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis

Pancreatic Cancer

China
Sun Yat-sen University

Not yet recruiting

A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment

Primary Mediastinal Large B Cell Lymphoma
Innate Pharma
AstraZeneca

Completed

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Neoplasms

United States, France
CellSight Technologies, Inc.
Stanford University

Completed

Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Squamous Cell Carcinoma of the Head and Neck

United States
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ACCLAIM)

NSCLC | PD-1

China
Cancer Research UK
Heptares Therapeutics Limited

Recruiting

HTL0039732 in Participants With Advanced Solid Tumours

Sarcoma | Neoplasms | Kidney Neoplasms | Uterine Cervical Neoplasms | Stomach Neoplasms | Head and Neck Neoplasms | Lung Neoplasms | Urinary Bladder Neoplasms | Colorectal Neoplasms | Pancreatic Neoplasms | Esophageal Neoplasms | Mesothelioma, Malignant | Prostatic Neoplasms, Castration-Resistant | Pheochromocytomas

United Kingdom
Second Military Medical University

Unknown

Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Peking University

Not yet recruiting

Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors

Digestive System Tumors

China
Merck Sharp & Dohme LLC

Completed

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)

Non-Small-Cell Lung Carcinoma
Zhejiang University
Shandong Cancer Hospital and Institute; First Hospital of China Medical University and other collaborators

Recruiting

A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma | Adjuvant Therapy

China
Shanghai Zhongshan Hospital
Jining Medical University; Cancer Hospital of Guangxi Medical University

Active, not recruiting

GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC

Biliary Tract Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

Head and Neck Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Peking University Cancer Hospital & Institute; Affiliated Cancer Hospital &... and other collaborators

Recruiting

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

Early-stage | Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type

China
Fudan University

Recruiting

PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC

Hepatocellular Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

NSCLC

China
Peking Union Medical College Hospital

Recruiting

irAE Prediction of Anti-PD-1/L1 in Lung Cancer

Lung Cancer | Immune Checkpoint Inhibitors

China
Jair Bar, M.D., Ph.D.
Merck Sharp & Dohme LLC

Completed

Anti PD-1 Neo-adjuvant Treatment for NSCLC (MK3475-223)

Non Small Cell Lung Carcinoma | Stage II | Stage I

Israel
Women's Hospital School Of Medicine Zhejiang University

Recruiting

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

Gestational Trophoblastic Neoplasia

China
Centre hospitalier de l'Université de Montréal...
Bristol-Myers Squibb

Completed

Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases

Melanoma | Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Brain Metastases, Adult | Clear-Cell Metastatic Renal Cell Carcinoma

Canada
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Completed

Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

Breast Cancer

China
Matthew Galsky
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Completed

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

Bladder Cancer | Urothelial Carcinoma

United States
Groupe Hospitalier Pitie-Salpetriere

Recruiting

JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors (JOCARDITE)

Heart Diseases | Cardiovascular Diseases | Vasculitis | Myocarditis | Cardiomyopathies | Pericarditis

France
Merck Sharp & Dohme LLC

Completed

Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)

Melanoma

Australia, South Africa, Spain, Sweden
TriSalus Life Sciences, Inc.

Recruiting

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Locally Advanced Pancreatic Adenocarcinoma

United States
Hangzhou Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

Esophageal Neoplasms | Esophageal Diseases | Esophageal Squamous Cell Carcinoma

China
AnaptysBio, Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata (AZURE)

Alopecia Areata

United States
Wuhan Union Hospital, China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy

Gastric Cancer | Randomized Controlled Study

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Colorectal Carcinoma
Nanfang Hospital of Southern Medical University

Recruiting

Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma (ANSWER)

Essential Tremor

China
AnaptysBio, Inc.

Recruiting

A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (RENOIR)

Rheumatoid Arthritis

United States, Argentina, Estonia, Georgia, Hungary, Mexico, Moldova, Republic of, Peru, Poland, Slovakia, Belgium, Canada, Germany, Italy, Spain
Affiliated Cancer Hospital & Institute of Guangzhou...

Not yet recruiting

Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

Non Small Cell Lung Cancer | Endostatin

China
Chinese PLA General Hospital

Unknown

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

Solid Tumor, Adult

China
Huazhong University of Science and Technology

Unknown

PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT

HCC

China
Shandong Provincial Hospital

Unknown

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

Relapsed/Refractory Non-Hodgkin's Lymphoma

China
University Medical Center Groningen

Active, not recruiting

MPDL3280A-imaging-IST-UMCG

Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression

Netherlands
Sun Yat-sen University

Recruiting

PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL

Classical Hodgkin Lymphoma | Refractory or Relapsed Classical Hodgkin Lymphoma

China
Akeso
Akeso Tiancheng, Inc

Active, not recruiting

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Memorial Sloan Kettering Cancer Center
AstraZeneca; Marker Therapeutics, Inc.

Completed

TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer

United States
Chinese PLA General Hospital

Unknown

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Pancreatic Cancer

China
The Second Hospital of Hebei Medical University

Recruiting

Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme

Glioblastoma Multiforme

China
Providence Health & Services
Bristol-Myers Squibb; Exelixis

Active, not recruiting

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Refractory Cutaneous Melanoma

United States
First People's Hospital of Hangzhou
Hangzhou Cancer Hospital

Recruiting

SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC

Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC

China
Peking University Third Hospital

Unknown

Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer. (CCRT+PD-1)

Cervical Cancer

China
Shanghai Zhongshan Hospital

Unknown

Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects

Advanced Solid Tumors

China
National Cancer Institute (NCI)

Recruiting

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

Thymic Carcinoma | Thymoma

United States
Merck Sharp & Dohme LLC

Completed

Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782)

Non-Small Cell Lung Cancer

United States, Canada, Hungary, Israel, Spain
Akeso
Akeso Pharmaceuticals, Inc.

Completed

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Ruhr University of Bochum

Unknown

Comparison of Two Endoscopically Placed Nasojejunal Probes

Investigation Time

Germany
Greg Durm, MD
Merck Sharp & Dohme LLC; Big Ten Cancer Research Consortium

Completed

Phase II Trial of Continuation Therapy in Advanced NSCLC

Non-Small-Cell Lung Cancer

United States

Search clinical trials for: PD-1, Anti-PD-1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations